Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions | Zendy

Cheng Michael L. | Zendy; Pectasides Eirini | Zendy; Hanna Glenn J. | Zendy; Parsons Heather A. | Zendy; Choudhury Atish D. | Zendy; Oxnard Geoffrey R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

Author(s) -

Cheng Michael L.,

Pectasides Eirini,

Hanna Glenn J.,

Parsons Heather A.,

Choudhury Atish D.,

Oxnard Geoffrey R.

Publication year - 2020

Publication title -

ca: a cancer journal for clinicians

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 62.937

H-Index - 168

eISSN - 1542-4863

pISSN - 0007-9235

DOI - 10.3322/caac.21650

Subject(s) - medicine , circulating tumor dna , precision oncology , patient care , solid tumor , clinical practice , oncology , clinical oncology , clinical decision making , profiling (computer programming) , intensive care medicine , medical physics , bioinformatics , cancer , family medicine , computer science , nursing , biology , operating system

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma ctDNA technologies in both commercial and academic laboratories are in routine or emerging use. The increasing integration of such testing to inform treatment decision making by oncology clinicians has complexities and challenges but holds significant potential to substantially improve patient outcomes. In this review, the authors discuss the current role of plasma ctDNA assays in oncology care and provide an overview of ongoing research that may inform real‐world clinical applications in the near future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research